Clinical Evaluation of the Abbott Alinity SARS-CoV-2 Spike-Specific Quantitative IgG and IgM Assays among Infected, Recovered, and Vaccinated Groups

Madhusudhanan Narasimhan; Lenin Mahimainathan; Ellen Araj; Andrew E. Clark; John Markantonis; Allen Green; Jing Xu; Jeffrey A. SoRelle; Charles Alexis; Kimberly Fankhauser; Hiren Parikh; Kathleen Wilkinson; Annika Reczek; Noa Kopplin; Sruthi Yekkaluri; Jyoti Balani; Abey Thomas; Amit G. Singal; Ravi Sarode; Alagarraju Muthukumar

doi:10.1128/jcm.00388-21

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

The coronavirus disease 19 (COVID-19) pandemic continues to impose a significant burden on global health infrastructure. While identification and containment of new cases remains important, laboratories must now pivot and consider an assessment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immunity in the setting of the recent availability of multiple COVID-19 vaccines.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Narasimhan et al. (2021) studied this question.

synapsesocial.com/papers/6a18de45a09e0bfd307c1208 https://doi.org/10.1128/jcm.00388-21

View Full Paper

Ask AI

Bookmark

Share

Clinical Evaluation of the Abbott Alinity SARS-CoV-2 Spike-Specific Quantitative IgG and IgM Assays among Infected, Recovered, and Vaccinated Groups

Ask about this paper

Abstract

Discussion

Cite This Study

Clinical Evaluation of the Abbott Alinity SARS-CoV-2 Spike-Specific Quantitative IgG and IgM Assays among Infected, Recovered, and Vaccinated Groups

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading